Medical/Pharmaceuticals
Discovery linking gut bacteria to cancer treatment wins the Bial Award in Biomedicine and earns €350,000 prize
A study published in Science reveals that a healthy gut microbiota can enhance the efficacy of immunotherapy used to treat cancer, while antibiotics may impair its effect by reducing intestinal microbiota diversity. PORTO, Portugal, Feb. 25, 2026 /PRNewswire/ -- An international consortium of 48...
Polaroid Therapeutics (PTx) Receives CE Mark for POLTX_Fiber™: the first application of APT™ to launch a new standard in wound care
Introducing Antimicrobial Polymer Technology (APT™) in POLTX_Fiber™, a Class IIb advanced wound care dressing that does not contribute to antimicrobial resistance: offering improved wound management through the prevention of bacterial colonization within the dressing. ZURICH, Feb. 25, 2026 /PRNe...
SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America
* New partnership combines Shilpa Biologicals' development and manufacturing capabilities with SteinCares' regional commercialization platform * Collaboration aims to expand patient access to cost-effective treatments and reinforces SteinCares' leadership in biosimilars across Latin America ...
Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
SHANGHAI and HONG KONG, Feb. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune d...
Direct Genome-Scale Mapping of Endonuclease Activity of the Human LINE-1 ORF2p Endonuclease
Nabsys and the Research Lab of Dr. Martin Taylor, Brown University, Present Data Using the OhmX™ Platform at AGBT 2026 PROVIDENCE, R.I., Feb. 25, 2026 /PRNewswire/ -- Nabsys 2.0, LLC (Nabsys), a pioneer in electronic genome mapping (EGM) technology, today announced new findings presented at the ...
AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)
HAMILTON, ON, Feb. 24, 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, announced that it has supplied the successful dosing of the first patient in Radiopharm Theranostics' First-in-Human Phase 1/2a clinical study of 177Lu‑BetaBart (RV‑01) by ...
Sanyou Biopharmaceuticals Announces New Strategic Investor; Liferiver Biotech Increases Its Stake, and Gree Group's Yanghe Investment Joins as a Strategic Shareholder
SHANGHAI, Feb. 24, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio"), a biotech company powered by super-trillion-molecule libraries and AI-driven technologies, today announced the completion of a significant equity restructuring. The shares previously held by Hai...
Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility
40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing precision medicine and delivering compounded value for NovaSeq X customers SAN DIEGO, Feb. 24, 2026 /PRN...
Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China
HANGZHOU, China, Feb. 24, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased GLP–1 receptor agonist. Under the agree...
ZEISS launches Collaborative Care application to strengthen continuity of care; new solution offers on-premises and cloud-based options
Built on the ZEISS Health Data Platform, ZEISS Collaborative Care offers eye care professionals a flexible way to collaborate – whether as a standalone cloud application or as an integrated extension of ZEISS FORUM – enabling secure data sharing, structured referrals, and real-time clinical coord...
"Would You Clone Yourself for a Cure?" Clonell Unveils White Paper on Fundamental Cures for 34 Incurable Diseases Using 'Human Cloning' Technology
Harnessing the vitality of a clone while neutralizing ethical controversies through a breakthrough 'Therapeutic Cloning' protocol—ushering in a new era of regenerative medicine to conquer cancer, Alzheimer's, and aging. YONGIN, South Korea, Feb. 23, 2026 /PRNewswire/ -- Human cloning has long be...
iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson's and First Enrollment in China's Randomized MSA Trial for NouvNeu004
CHENGDU, China, Feb. 23, 2026 /PRNewswire/ -- The global race to treat neurodegenerative diseases has reached a new tempo as iRegene Therapeutics pushes its cell therapy pipeline into key clinical stages in the U.S. andChina. Concurrently, the company's "AI + Chemical Induction" platform saw its...
Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
TAIPEI, Feb. 23, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Arrotex Pharmaceuticals Pty Ltd. ("Arrotex"), for exclusive rights to the commercialization of clobetasol propio...
Vitafoods Asia 2026 Expands by 30%: A Bigger, More Dynamic Trade Event with Exciting New Features & Increased International Participation
BANGKOK, Feb. 23, 2026 /PRNewswire/ -- With a remarkable 30% growth in size and participation, Vitafoods Asia 2026 organised by Informa Markets, is set to redefine the nutraceutical industry in Asia, offering unparalleled opportunities for innovation and collaboration. The event will feature an ...
CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
* Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for stage III non-small cell lung cancer (NSCLC). This marks the second indication approved for the product in the UK. ...
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the year ended December 31, 2025. FY 2025 key results1 Group performance2: Double-digit revenue growth and positive adju...
TraceLink Named to RXinsider's 2026 Pharmacy500 for Powering Digital Network Orchestration Across the Regulated Pharmacy Supply Chain
The recognition highlights TraceLink's Business-to-Network Integrate-Once™ platform that enables end-to-end digitalization, interoperable compliance execution, and operational resilience at industry scale Summary TraceLink is recognized for delivering a unified, network-based platform that help...
3Shape Boosts Dental Lab Speed and Accuracy with AI-Powered Workflows
COPENHAGEN, Denmark, Feb. 19, 2026 /PRNewswire/ -- At LMT LabDay today, 3Shape showcases its AI-powered and integrated workflows that help dental labs work faster, reduce errors, and handle more cases efficiently. A reliable bite setup in seconds Scans from intraoral scanners can sometimes inclu...
Cambrex Announces Cornell Professor Song Lin as Recipient of the 2025 Snapdragon Prize for Innovation in Chemistry Technology
EAST RUTHERFORD, N.J., Feb. 19, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) and Snapdragon Chemistry, a Cambrex company, are proud to announce that Dr. Song Lin, Tisch University Professor in chemistry and chemical biology at Cornell U...
A World-First in Neonatal Care: Japan Approves Prolacta Bioscience's 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants
Japan's Ministry of Health, Labour and Welfare (MHLW) Approves
PreemieFort® Enteral Solution asPrescription Medicine in the NICU
DUARTE, Calif., Feb. 19, 2026 /PRNewswire/ -- Prolacta Bioscience®
Week's Top Stories
Most Reposted
Visa Working Capital Index: Asia Pacific CFOs Call for Flexible, Digital Finance Solutions
[Picked up by 308 media titles]
2026-03-24 14:00HOY Unveils a Powerhouse Line-up of Talent for its Bold New Chapter
[Picked up by 306 media titles]
2026-03-20 09:36Indonesia's P2P Lending Grows 25%, JULO Strengthens Credit Quality
[Picked up by 298 media titles]
2026-03-26 18:18MetaOptics progresses on its strategic growth and leadership transition initiatives
[Picked up by 283 media titles]
2026-03-20 08:15ART CENTRAL COMMENCES DISCOVERY-LED ELEVENTH EDITION
[Picked up by 277 media titles]
2026-03-25 16:51